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Owing to the unique opportunity to assess individuals before and after they develop depression within a short timeframe, interferon-α
(IFN-α) treatment for chronic hepatitis C virus (HCV) infection is an ideal model to identify molecular mechanisms relevant to major
depression, especially in the context of enhanced inflammation. Fifty-eight patients were assessed prospectively, at baseline and monthly
over 24 weeks of IFN-α treatment. New-onset cases of depression were determined using the Mini International Neuropsychiatric
Interview (MINI). Whole-blood transcriptomic analyses were conducted to investigate the following: (1) baseline gene expression
differences associated with future development of IFN-α-induced depression, before IFN-α, and (2) longitudinal gene expression changes
from baseline to weeks 4 or 24 of IFN-α treatment, separately in those who did and did not develop depression. Transcriptomics data
were analyzed using Partek Genomics Suite (1.4-fold, FDR adjusted p⩽ 0.05) and Ingenuity Pathway Analysis Software. Twenty patients
(34%) developed IFN-α-induced depression. At baseline, 73 genes were differentially expressed in patients who later developed
depression compared with those who did not. After 4 weeks of IFN-α treatment, 592 genes were modulated in the whole sample,
representing primarily IFN-α-responsive genes. Substantially more genes were modulated only in patients who developed depression
(n= 506, compared with n= 70 in patients who did not), with enrichment in inflammation-, neuroplasticity- and oxidative stress-related
pathways. A similar picture was observed at week 24. Our data indicate that patients who develop IFN-α-induced depression have an
increased biological sensitivity to IFN-α, as shown by larger gene expression changes, and specific signatures both as predictors and as
correlates.
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INTRODUCTION
The development of clinically significant depression during
interferon-α (IFN-α) therapy for chronic hepatitis C virus
(HCV) infection is common, with an incidence of up to 45%
(Asnis and De La Garza, 2006). Extensive research has been
conducted to understand the biological systems involved in
the development of IFN-α-induced depression and to
identify biological predictors associated with an enhanced
risk to develop depressive symptoms. However, the mole-
cular mechanisms are still unclear. Owing to the unique
opportunity to assess individuals before and after they
develop depression within a short period of time (weeks
rather than months or years), this model can also crucially
identify mechanisms relevant to major depression at large, or
at least in the context of increased inflammation. Previous
studies have used hypothesis-based approaches, focussed
on specific biomarkers (Capuron et al, 2003; Lotrich et al,
2013; Raison et al, 2009). However, IFN-α activates many
biological systems; therefore, a hypothesis-free approach
may identify novel molecular mechanisms that predict or
correlate with the development of depression.
Peripherally, IFN-α acutely induces the production and
release of other innate immune cytokines such as
interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α)
(Raison et al, 2008). These cytokines are putatively involved
in the depressogenic action of IFN-α. Higher serum or
plasma levels of these (and other) pro-inflammatory markers
have been shown to be associated with an increased risk of
major depressive disorder (Dowlati et al, 2010). Our own
work has shown increased inflammation in the blood of
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depressed patients when compared with healthy controls
together with an association between higher cytokine levels
and lack of antidepressant response (Cattaneo et al, 2013).
Post-mortem gene expression studies show an upregulation
of a variety of pro- and anti-inflammatory cytokines in the
prefrontal cortex of depressed patients (Shelton et al, 2011),
thus indicating that peripheral inflammation may correlate
with central abnormalities. However, the link between
increased peripheral inflammation and IFN-α-induced
depression is still unclear and studies report mixed results.
For example, Wichers et al (2006) report a difference
in plasma levels of IL-6 between patients who develop
IFN-α-induced depression and those who do not, but no
difference in plasma levels of TNF-α. Conversely, Raison
et al (2008) report increased plasma concentrations of TNF-α
to be significantly correlated with increased depression
scores but no correlation was observed for IL-6.
A consolidated method to investigate the pathogenesis of
psychiatric disorders is the use of peripheral blood to
measure gene expression (mRNA) levels, which may be
considered indicative of gene expression profiles in the brain
(Hepgul et al, 2013). Several studies have shown that blood
cells share > 80% of the transcriptome with other tissues,
including the brain (Liew et al, 2006). A comparison of the
transcriptional profiling of 79 human tissues showed that
whole blood shares significant gene expression similarities
with multiple brain tissues, in particular for genes encoding
for neurotransmitter receptors and transporters, stress
mediators, cytokines, hormones, and growth factors, all of
which are relevant to depression (Sullivan et al, 2006). Global
gene profiling in IFN-α-treated cells has shown a number of
IFN-stimulated genes (Wang and Campbell, 2005) such as
IFN-induced 15-kDa protein (ISG15), ubiquitin-specific
proteinase 18 (USP18), IFN-induced 10-kDA protein (IP-10
or chemokine (C-X-C motif) ligand 10 (CXCL10)), signal
transducers and activators of transcription (STAT1), and
IFN-induced guanylate-binding protein 3 (GBP3), and again
with similarities between immune and brain cells (Wang
et al, 2008). Of specific relevance to the present study, to date
only five studies have investigated peripheral blood gene
expression changes in the development of IFN-α-induced
depression. Three of these studies used a candidate gene
approach, thus limiting the identification of novel or hitherto
unknown mechanisms (Birerdinc et al, 2012; Krueger et al,
2011; Pawlowski et al, 2014), whereas two studies used
transcriptomics (Felger et al, 2012; Schlaak et al, 2012).
Felger et al (2012) used mRNA from isolated peripheral
blood mononuclear cells (PBMCs) of 11 HCV patients before
and after 12 weeks of IFN-α treatment. They found 252
upregulated and 116 downregulated genes after 12 weeks of
IFN-α treatment. However, the sample size was small (only
four patients developed depressive symptoms) and only two
genes were found to be differentially expressed in patients
with depression: the 2’-5’-oligoadenylate synthetase 2 (OAS2;
upregulated) and the high-affinity IgE receptor (FCER1A;
downregulated). In the other transcriptomics study, blood
mRNA was examined 12 h before and 12 h after the first
injection of IFN-α (Schlaak et al, 2012). IFN-α-induced
depression (after at least 3 months of treatment) was found
to be associated with upregulation of 15 genes, suggesting
that very early responses to IFN-α are related to the
development of depression.
In this study, we have used whole-blood transcriptomics to
investigate, in a large sample of HCV patients, the following:
(1) baseline gene expression differences associated with future
development of IFN-α-induced depression, before IFN-α
administration, and (2) longitudinal changes in gene expres-
sion from baseline to treatment week 4 (TW4) and TW24 of
IFN-α, separately in those who did and did not develop
depression. In addition, a small number of candidate cytokines
were assessed in the plasma of patients at the same time points.
MATERIALS AND METHODS
Study Design
This was a prospective cohort study, evaluating patients at
baseline and monthly over 24 weeks of IFN-α treatment.
Blood samples for whole-blood mRNA analysis were
collected in PAXgene Blood RNA Tubes (PreAnalytiX,
Switzerland) and for plasma cytokine measurement in 2 ml
K3EDTA tubes (ThermoFisher Scientific, Massachusetts,
USA) using standard protocols, at baseline and at TW4
and TW24. We recruited 58 participants from the outpatient
liver departments of three London hospitals: King’s College
Hospital, Guy’s and St Thomas’ Hospital, and St George’s
Hospital. Eligible participants were adults with chronic
HCV infection due to commence combination antiviral
therapy with IFN-α and ribavirin for at least 24 weeks; this
comprised weekly subcutaneous IFN-α injections (1.5 μg per
kg of body weight) and daily ribavirin tablets (800–1400 mg/
day orally, in 2 divided doses). Exclusion criteria included
the following: age below 18 years, current diagnosis
(at baseline) of major depressive disorder, autoimmune
disorder, current use of antidepressants, lack of English
language, and co-infection with HIV or hepatitis B. Written
informed consent was obtained from all participants. The
research team did not interfere with the usual clinical
practice; when the research team detected depression
development during IFN-α, this information was commu-
nicated to the treating hepatitis clinical team, who in turn
decided whether or not to refer to liaison psychiatry services.
The study was approved by the King’s College Hospital
Research Ethics Committee (Ref: 10/H0808/30).
Questionnaires, Clinical Assessment, and Sample
Description
The Mini International Neuropsychiatric Interview (MINI)
was administered at baseline, to assess current depression or
a previous history of depression, and at follow-up assess-
ments for the detection of new-onset cases of depression.
The MINI is a structured diagnostic interview for psychiatric
disorders according to the Diagnostic and Statistical Manual
of Mental Disorders, 4th Edition and the International
Statistical Classification of Diseases and Related Health
Problems 10th Revision (Sheehan et al, 1998). For the
purpose of this study, we only focused on the detection and
diagnosis of major depressive episode. In addition, the
severity of depressive symptoms was assessed using the
Inventory of Depressive Symptomatology (IDS) (Rush et al,
1986). IDS scores were significantly higher at TW4 and
TW24 when compared with baseline (20.8± 1.7 vs 11.6± 1.5,
po0.001 and 22.9± 2.0 vs 11.6± 1.5, po0.001, respectively),
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whereas there was no significant difference between TW4
and TW24 (20.8± 1.7 vs 22.9± 2.0, p= 0.2).
The depressed group was defined by a MINI diagnosis of
major depressive episode at any time point during the
24 weeks. Four (7%) patients developed depression by
TW4 and 20 (34%) patients developed depression by TW24,
whereas 38 patients (66%) did not develop depression.
Two patients were started on antidepressant treatment after
they developed IFN-α-induced depression. The socio-
demographic and clinical characteristics of the sample are
presented in Table 1. Patients who developed depression
were significantly more likely to have a previous history of
depression, be unemployed, and have higher baseline
depression scores. These three variables were interrelated
and, indeed, those with a history of depression were more
likely to be unemployed and to have higher depression scores
at baseline (data not shown). Given this interrelation and the
existing evidence for the presence of mood or anxiety
Table 1 Socio-Demographic and Clinical Characteristics of the Sample
Whole sample
n=58
Depressed patients
n=20
Non-depressed patients
n= 38
Age (years)
Mean± SEM 44.7± 1.6 42.4± 2.5 45.9± 2.0 t= 1.1, df= 56, p= 0.3
Gender
Male 45 (78%) 15 (75%) 30 (79%) x2= 0.12, p= 0.5
Ethnicity
White British 27 (47%) 8 (40%) 19 (50%) x2= 0.53, p= 0.3
Other 31 (53%) 12 (60%) 19 (50%)
Education level
University/A level 23 (41%) 8 (40%) 15 (42%) x2= 0.01, p= 0.6
GCSEs/no qualifications 33 (59%) 12 (60%) 21 (58%)
Employment
Full-time 32 (55%) 7 (35%) 25 (66%) x2= 5.02, po0.05
Unemployed 26 (45%) 13 (65%) 13 (34%)
Relationship status
Single 27 (47%) 8 (40%) 19 (50%) x2= 0.53, p= 0.3
Married/cohabiting 31 (53%) 12 (60%) 19 (50%)
History of depression 19 (33%) 10 (50%) 9 (24%) x2= 4.12, po0.05
Family history of psychiatric illness 14 (31%) 5 (36%) 9 (29%) x2= 0.20, p= 0.5
Baseline depression scores 11.6± 1.5 16.1± 3.0 9.2± 1.6 t=− 2.3, df= 56, po0.05
TW4 depression scores 20.8± 1.7 28.6± 2.5 16.6± 1.9 t=− 3.8, df= 56, po0.001
TW24 depression scores 22.9± 2.0 37.1± 3.3 15.5± 1.6 t=− 6.7, df= 56, po0.001
Alcohol use
Mean± SEM 4.2± 0.9 5.3± 2.1 3.7± 0.8 t=− 0.9, df= 54, p= 0.4
HCV genotype
1 and 4 13 (22%) 6 (30%) 7 (18%) x2= 1.01, p= 0.2
2 and 3 45 (78%) 14 (70%) 31 (82%)
HCV viral load (million)
Mean± SEM 2.2± 2.8 2.1± 0.7 2.2± 0.5 t= 0.2, df= 54, p= 0.8
Fibroscan scores (kpa)
Mean± SEM 9.9± 1.2 11.1± 2.7 9.3± 1.3 t=− 0.7, df= 44, p= 0.5
Numbers in bold indicate significant results.
Transcriptomics in interferon-α-induced depression
N Hepgul et al
2504
Neuropsychopharmacology
symptoms before treatment as a risk factor (Dieperink et al,
2003; Lotrich et al, 2007), baseline depression scores were
used as a covariate in all statistical analyses.
RNA Isolation and Transcriptomics Analyses
Isolation of total RNA was performed using the PAXgene
blood miRNA kit according to the manufacturer’s protocol
(PreAnalytiX, Hombrechtikon, CHE). RNA quantity and
quality were assessed by evaluation of the A260/280 and
A260/230 ratios using a Nanodrop spectrophotometer
(NanoDrop Technologies, Delaware, USA) and samples kept
at − 80 °C until processing for whole-genome transcrip-
tomics analyses. Microarray assays were performed following
the protocol described in the Affymetrix GeneChip Expression
Analysis technical manual (Affymetrix, California, USA).
Briefly, 250 ng RNA were used to synthesize cDNA with the
Ambion WT Expression Kit (ThermoFisher Scientific), which
was then purified, fragmented, labeled, and hybridized onto
Human Gene 1.1 ST Array Strips (Affymetrix). The reactions
of hybridization, fluidics, and imaging were performed on the
Affymetrix GeneAtlas platform (Affymetrix) instrument
according to the manufacturer’s protocol. Validation of
transcriptomics was performed using real-time PCR (full
details in Supplementary Materials). Correlation between the
Affymetrix and real-time values was 0.99 (data presented in
Supplementary Table S1).
Plasma Cytokine Measurement
Blood samples were collected in 2 ml K3EDTA tubes
(ThermoFisher Scientific). On arrival to the laboratory,
samples were centrifuged at 1500 g for 15 min at room
temperature and plasma were removed and frozen at − 80 °C
until processing for cytokine measurement. All candidate
proteins were measured using Magnetic Luminex Perfor-
mance Multiplex Assay (R&D Systems, Minneapolis, USA),
using the customized 7-plex Human High Sensitivity
Cytokine Premixed kit (R&D, FCSTM14). From the
cytokines available for ‘high-sensitivity’ measurement, we
chose five cytokines known to be stimulated by IFN-α (IL-1β,
IL-2, IL-6, IFN-γ, and TNF-α (Taylor and Grossberg, 1998))
and two that are inhibited (IL-7 (Su et al, 1997) and IL-17A
(Cui et al, 2014)). All samples were assayed according to the
manufacturer’s protocol and the results analyzed using
SoftMax Pro V4.8 (full details in Supplementary Materials).
IFN-γ levels were below detection limit for most samples and
therefore were not analyzed further.
Statistical and Bioinformatic Analyses
Data were analysed using IBM SPSS V20. Continuous
variables are presented as mean± SEM. Differences in clinical
and socio-demographic variables between patients who
developed IFN-α-induced depression and those who did not
were analyzed using independent samples t-tests. Changes in
depression scores between time points were analyzed
using paired samples t-tests. A repeated-measures ANCOVA
(with baseline IDS scores as a covariate) was performed, to
test for differences in plasma cytokine levels as an effect of
IFN-α treatment (time effect) and in relation to depression
development (group effect). For gene expression data, CEL
files were imported into Partek Genomics Suite V6.6 for data
visualization and quality control. In summary (full details in
Supplementary Materials), background correction was con-
ducted using Robust Multi-strip Average (Irizarry et al, 2003)
and Quantile Normalization (Bolstad et al, 2003) was used to
normalize the distribution of probe intensities among different
microarray strips. Summarization was conducted using
a linear median polish algorithm (Tukey, 1977) to integrate
probe intensities and compute expression levels for each gene
transcript. To assess the effect of IFN-α treatment, a multiple
linear contrast over time was performed and gene lists
obtained by applying cutoffs of both p-value (FDR corrected)
of ⩽ 0.05 and a minimum absolute fold change of 1.4.
Ingenuity Pathway Analysis Software was used to identify
regulation of molecular signaling pathways.
RESULTS
Baseline Gene Expression Differences Predicting the
Development of IFN-α-Induced Depression
We first examined differences in gene expression at baseline
(before starting IFN-α) and compared the profile of patients
who subsequently did and who did not develop IFN-α-
induced depression. Using the above-mentioned cutoff
criteria and baseline depression scores as a covariate, we
found 73 differentially modulated genes (see Supplementary
Table S2). Pathway analysis of these 73 genes identified 24
pathways including inflammation-, neuroplasticity- and
oxidative stress-related pathways, such as IL-1 signaling,
NRF2-mediated oxidative stress response, and axonal
guidance signaling. These pathways are presented in
Figure 1 and Table 2. In addition, we also compared plasma
cytokine levels at baseline; however, there were no significant
differences between the two groups (all p-values 40.2; see
Supplementary Table S3).
Genes Modulated by IFN-α at TW4 in the Whole Sample
and in Relation to Development of IFN-α-Induced
Depression
We identified genes modulated by IFN-α, by comparing the
expression profile of the sample at TW4 with the profile at
baseline. IFN-α modulated 592 genes, including well-known
Figure 1 Role classification of pathways differentially modulated at
baseline between patients who develop depression compared with those
who do not.
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IFN-α targets such as IFN-α-inducible protein 27 (IFI27,
FC=+32.05), IFN-induced protein 44-like (IFI44L,
FC=+11.59), USP18 (FC=+4.39), ISG15 ubiquitin-like
modifier (ISG15, FC=+2.70), and CXCL10 (FC=+1.84).
Subsequently, we investigated genes modulated by IFN-α
separately in patients who developed depression (n= 20) and
those who did not (n= 38). We found 506 genes modulated
only in patients who developed depression (see
Supplementary Table S4) and 70 genes modulated only in
patients who did not develop depression (see Supplementary
Table S5). We focussed our further analyses on the 506 genes
specifically modulated in patients who developed depression.
We found 224 upregulated and 284 downregulated genes,
including genes previously found to be associated with
depression such as CXCL10 (FC=+2.13) and insulin-like
growth factor 2 mRNA binding protein 2 (IGF2BP2,
FC=+1.88). Pathway analysis of these 506 genes identified
65 pathways including those related to inflammation (IL-1,
IL-6, and IL-8 signaling, glucocorticoid receptor (GR)
signaling, triggering receptor expressed on myeloid cells 1
signaling, and nuclear factor-κB cells (NF-κB) signaling),
neuroplasticity (extracellular signal-regulated kinase
5 (ERK5) signaling and axonal guidance signaling), and
oxidative stress (NRF2-mediated oxidative stress response,
p53 signaling, and production of nitric oxide and reactive
oxygen species in macrophages). These pathways are
presented in Figure 2 and Table 3.
Finally, we conducted a two-way repeated-measure
ANCOVA (with baseline depression scores as a covariate)
to investigate changes in plasma cytokine levels between
TW4 and baseline, and also in relation with depression
development. We found a significant effect of IFN-α (time
effect) for decreasing IL-1β (p= 0.043) and increasing IL-6
(p= 0.013), IL-17A (p= 0.022), and TNF-α (po0.001),
but no effect of depressive status (group effect, all p-values
40.3) nor time by group effect (all p-values 40.2)
(see Supplementary Table S3).
Genes Modulated by IFN-α at Week 24 in the Whole
Sample and in Relation to Development of IFN-α-
Induced Depression
In order to assess whether IFN-α-modulated changes persisted
further down the treatment course, we compared the gene
expression profile of patients at TW24 with the profile at
baseline. Similar to TW4, modulation of several IFN-α target
genes were observed in the whole sample, including IFI27
(FC=+34.20), IFI44L (FC=+11.78), USP18 (FC=+4.72),
ISG15 (FC=+2.80), and CXCL10 (FC=+2.52). In addition,
we observed modulation of other known IFN-α target genes,
which we did not see at TW4, such as GBP3 (FC=+1.45) and
STAT1, 91 kDa (FC=+1.45). We found 285 genes modulated
only in patients who developed depression (see
Supplementary Table S6) and 121 genes modulated only in
patients who did not develop depression (see Supplementary
Table S7). We focussed our further analyses on the 285 genes
that were modulated in patients who developed depression.
These included 215 upregulated and 112 downregulated genes.
Pathway analysis of these 285 genes identified 20 pathways.
Interestingly, as indicated in Table 3, eight pathways were
modulated at both TW4 and TW24, including ERK5
signaling, stress-activated protein kinase/Jun N-terminal
kinase (SAPK/JNK) signaling, and the glutathione redox
reactions I pathway. The full list of 20 pathways and their role
classifications can be seen in Supplementary Table S8 and
Supplementary Figure S9, respectively.
Again, we conducted a two-way repeated-measure
ANCOVA (with baseline depression scores as a covariate),
to investigate changes in plasma cytokine levels between
TW24 and baseline, and in relation with depression
Table 2 Pathways Differentially Modulated at Baseline Between
Patients Who Develop Depression Compared With Those Who
Do Not (p⩽ 0.05)
Pathway Molecules
Ephrin B signaling GNAT2, NCK2, ROCK1, GNG2
Coagulation system A2M, PROS1, SERPIND1
G alpha q signaling RGS18, PPP3R1, ROCK1, GNG2
Ephrin receptor signaling GNAT2, NCK2, ROCK1, GNG2
NRF2-mediated oxidative stress response DNAJC8, DNAJA2, GSTM3, GPX2
Cardiac hypertrophy signaling PPP3R1, GNAT2, ROCK1, GNG2
CCR3 signaling in eosinophils PLA2G10, ROCK1, GNG2
Netrin signaling PPP3R1, NCK2
Axonal guidance signaling PPP3R1, GNAT2, NCK2, ROCK1,
GNG2
CXCR4 signaling GNAT2, ROCK1, GNG2
Actin nucleation by ARP-WASP complex NCK2, ROCK1
Role of NFAT in regulation of the immune
response
PPP3R1, GNAT2, GNG2
RhoGDI signaling GNAT2, ROCK1, GNG2
Thrombin signaling GNAT2, ROCK1, GNG2
Integrin signaling NCK2, ROCK1, LIMS1
G Beta gamma signaling GNAT2, GNG2
Signalling by Rho family GTPases GNAT2, ROCK1, GNG2
IL-1 signaling GNAT2, GNG2
Phospholipase C signaling PPP3R1, PLA2G10, GNG2
fMLP signaling in neutrophils PPP3R1, GNG2
Androgen signalling GNAT2, GNG2
Extrinsic prothrombin activation pathway PROS1
Glutathione redox reactions I GPX2
Relaxin signaling GNAT2, GNG2
Figure 2 Role classification of pathways differentially modulated at
treatment week 4 (TW4) specifically in patients who develop depression.
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Table 3 Pathways Differentially Modulated at TW4 Specifically in Patients Who Develop Depression (p⩽ 0.05)
Pathway Molecules
Aryl hydrocarbon receptor signaling FOS, NCOR2, HSPB1, IL1B, ALDH1A1, NQO2, ALDH5A1, NFIA, MGST1, TFDP1, MGST3, NRIP1
IL-6 signaling FOS, A2M, HSPB1, IL1RN, IL1B, TNFAIP6, CD14, IL6R, AKT2, IL6ST
ERK5 signalinga FOS, SGK1, GNA12, WNK1, GAB1, MAP3K3, IL6ST
Pentose phosphate pathwaya TKT, PGD, TALDO1
NRF2-mediated oxidative stress response FOS, DNAJA4, DNAJC8, DNAJC6, GCLC, ABCC4, DNAJA2, DNAJC15, NQO2, MGST1, MGST3
Phenylethylamine degradation Ia ALDH2, AOC3
NF-κB signaling BMPR2, TNFSF13B, IL1RN, IL1B, AZI2, TLR6, PELI1, AKT2, MAP3K3, PLCG2
LXR/RXR activation NCOR2, S100A8, IL1RN, IL1B, MMP9, ORM1, CD14, PTGS2
Ephrin B signaling ACP1, EPHB4, GNAT2, GNA12, ROCK1, GNG2
Production of nitric oxide and reactive oxygen species in
macrophages
FOS, IFNGR1, NCF4, S100A8, ORM1, NCF1, SIRPA, AKT2, MAP3K3, PLCG2
IL-8 signaling FOS, MMP9, CXCR2, PTGS2, CXCR1, GNA12, ROCK1, BCL2L1, GNG2, AKT2
Phosphatidylglycerol biosynthesis II (non-plastidic) ABHD5, AGPAT9, PGS1
GR signaling KAT2B, NCOR2, IL1B, PPP3CA, AKT2, FOS, A2M, IL1RN, DUSP1, SGK1, PTGS2, BCL2L1, NRIP1
Pentose phosphate pathway (non-oxidative branch)a TKT, TALDO1
Rapoport–Luebering glycolytic shunt BPGM, MINPP1
Glutathione redox reactions Ia CLIC2, MGST1, MGST3
Fatty acid alpha oxidation ALDH1A1, PTGS2, ALDH2
Pancreatic adenocarcinoma signalinga NOTCH1, MMP9, PTGS2, E2F2, BCL2L1, TFDP1, AKT2
RAR activation FOS, KAT2B, NCOR2, RPL7A, PML, DUSP1, ALDH1A1, AKT2, NRIP1, PRKAR1A
Superpathway of inositol phosphate compounds PPP1R8, DUSP1, PPTC7, ACP1, PPP4R1, SIRPA, PPP3CA, MINPP1, INPP5A, PLCG2
Pyrimidine deoxyribonucleotides de novo biosynthesis I AK5, NME4, RRM2B
Role of macrophages, fibroblasts and endothelial cells in
rheumatoid arthritis
TNFSF13B, F2RL1, IL1B, IL6R, PPP3CA, AKT2, IL6ST, PLCG2, FOS, IL1RN, C5AR1, ROCK1, TLR6
G beta gamma signaling GNAT2, GNA12, GNG2, AKT2, PLCG2, PRKAR1A
Eicosanoid signaling CYSLTR2, DPEP2, PTGS2, FPR2, TBXAS1
Colorectal cancer metastasis signaling FOS, IFNGR1, MMP9, PTGS2, IL6R, BCL2L1, TLR6, GNG2, AKT2, IL6ST, PRKAR1A
D-myo-inositol-5-phosphate metabolism PPP1R8, DUSP1, PPTC7, ACP1, PPP4R1, SIRPA, PPP3CA, PLCG2
Granulocyte adhesion and diapedesis HSPB1, IL1RN, IL1B, MMP9, CXCL10, C5AR1, CXCR2, FPR2, HRH2
Superpathway of D-myo-inositol (1,4,5)-trisphosphate
metabolism
IMPA2, MINPP1, INPP5A
Prostanoid biosynthesis PTGS2, TBXAS1
PPAR signaling FOS, NCOR2, IL1RN, IL1B, PTGS2, NRIP1
EIF2 signalinga RPL5, RPL7A, RPL13A, EIF4A1, RPL41, RPS2, AKT2, RPS15, AGO4
p53 signaling KAT2B, PML, BCL2L1, AKT2, RRM2B, PMAIP1
Agranulocyte adhesion and diapedesis IL1RN, IL1B, MMP9, CXCL10, C5AR1, CXCR2, CXCR1, AOC3, MYH9
Toll-like receptor signaling FOS, IL1RN, IL1B, CD14, TLR6
Cholecystokinin/gastrin-mediated signaling FOS, IL1RN, IL1B, PTGS2, GNA12, ROCK1
D-myo-inositol (1,4,5,6)-tetrakisphosphate biosynthesis PPP1R8, DUSP1, PPTC7, ACP1, PPP4R1, SIRPA, PPP3CA
D-myo-inositol (3,4,5,6)-tetrakisphosphate biosynthesis PPP1R8, DUSP1, PPTC7, ACP1, PPP4R1, SIRPA, PPP3CA
Cardiac hypertrophy signaling HSPB1, GNAT2, GNA12, IL6R, ROCK1, GNG2, PPP3CA, MAP3K3, PLCG2, PRKAR1A
Sorbitol degradation I SORD
TREM1 signaling NLRP12, IL1B, TLR6, AKT2, PLCG2
Pyrimidine ribonucleotides interconversion ENTPD1, AK5, NME4
Axonal guidance signaling MMP9, EPHB4, ADAM8, GNAT2, ARHGEF12, GNA12, TUBG1,PLXNC1, ADAM19, PPP3CA, AKT2,
PLCG2, PRKAR1A, TUBA1A, ROCK1, GNG2
HGF signaling FOS, PTGS2, GAB1, AKT2, MAP3K3, PLCG2
Molecular mechanisms of cancer NOTCH1, GNAT2, ARHGEF12, GNA12, GAB1, AKT2, PRKAR1A, FOS, RALB, BMPR2, E2F2, BCL2L1,
TFDP1, PMAIP1
Relaxin signaling FOS, MMP9, GNAT2, GNA12, GNG2, AKT2, PRKAR1A
Pyrimidine ribonucleotides de novo biosynthesis ENTPD1, AK5, NME4
Acute phase response signaling FOS, A2M, IL1RN,I L1B, ORM1, IL6R, AKT2, IL6ST
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development. We found a significant effect of IFN-α (time
effect) for increasing IL-6 (p= 0.012), IL-17A (p= 0.008), and
TNF-α (po0.001), but again no effect of depressive status
(group effect, all p-values 40.4) nor time by group
interaction (all p-values40.1) (see Supplementary Table S3).
DISCUSSION
To our knowledge, this is the first study to use a peripheral
blood transcriptomics approach to identify both predictors
of future development of IFN-α-induced depression and
biological pathways associated with the development of
depression. Already before IFN-α, patients who later develop
depression show significant differences in the expression of
several pathways compared with those who do not; in
addition, by TW4 they show specific longitudinal changes in
similar and additional pathways, related to inflammation,
neuroplasticity, and oxidative stress. We replicate a number
of previously identified IFN-responsive genes. For example,
Wang et al (2008) listed ISG15, USP18, IP-10/CXCL10,
STAT1, and IFN-induced GBP3 as some of the most highly
expressed IFN responsive genes and we show changes in all
of these genes following IFN-α administration. In addition,
we replicate IFN-α-stimulated genes found in cultured neurons
including IRF7, PNPT1, and IFIH1 (Wang and Campbell,
2005). Finally, we replicate 100 genes (35%) and 5 pathways,
shown to be responsive to IFN-α by Felger et al (2012). These
consistencies strengthen the validity of our findings.
Among the most significant differentially expressed genes
at baseline (predictors), we find upregulation of ubiquitin-
fold modifier 1 (UFM1) and eukaryotic translation
initiation factor 4B (EIF4B) in patients who later develop
IFN-α-induced depression. The exact functions of UFM1 are
poorly understood; however, it has been shown to be
involved in heart disease (Azfer et al, 2006) and diabetes
(Lemaire et al, 2011) (conditions that present frequent
comorbidity with depression), as well as schizophrenia
(Rubio et al, 2013). EIF4B is a downstream component of
the mammalian target of rapamycin (mTOR) signaling
pathway. There is abundant evidence linking mTOR
signaling to synaptic plasticity, memory, and psychiatric
disorders (Hoeffer and Klann, 2010). Although we see
increased expression of EIF4B in our patients who subse-
quently develop IFN-α-induced depression, Jernigan et al
(2011) report significant reductions in EIF4B (and mTOR)
expression in the prefrontal cortex of depressed subjects. The
sample used by Jernigan et al (2011) were on overage more
than 10 years older and were predominantly suicide victims,
which may account for these discrepant results. Also at
baseline, we identified 24 pathways, some related to
inflammation (IL-1 and CCR3 signaling), neuroplasticity
(axonal guidance and netrin signaling), and oxidative stress
(NRF2-mediated oxidative stress response and glutathione
redox reactions I signaling). Some of these pathways were
also significantly regulated longitudinally in patients who
develop depression (see below).
Following 4 weeks of IFN-α treatment, we find that the
number of modulated genes is more than seven times larger
in patients who develop depression than in patients who do
not, suggesting that patients who develop IFN-α-induced
depression have an increased biological sensitivity to IFN-α.
Of note, only four patients were depressed at TW4, while the
majority became depressed between week 4 and 12 (n= 11)
or between week 12 and 24 (n= 5); therefore, most patients
classified as depressed in these analyses were on a trajectory to
Table 3 Continued
Pathway Molecules
Role of NFAT in regulation of the immune response FOS, SYK, GNAT2, GNA12, GNG2, PPP3CA, AKT2, PLCG2
Xenobiotic metabolism signaling NCOR2, GCLC, IL1B, ALDH1A1, UGT2B7, NQO2, ALDH5A1, MGST1, MAP3K3, MGST3, NRIP1
3-Phosphoinositide degradation PPP1R8, DUSP1, PPTC7, ACP1, PPP4R1, SIRPA, PPP3CA
Triacylglycerol biosynthesis ABHD5, AGPAT9, LPPR2
Communication between innate and adaptive immune
cells
TNFSF13B, IL1RN, IL1B, CXCL10, TLR6
Cardiolipin biosynthesis II PGS1
GM-CSF signaling CSF2RA, BCL2L1, PPP3CA, AKT2
G alpha i signaling RALB, CXCR2, FPR2, P2RY14, GNG2, PRKAR1A
Aldosterone signaling in epithelial cells HSPB1, DNAJC8, DNAJC6, DUSP1, SGK1, DNAJC15, PLCG2
CDP-diacylglycerol biosynthesis I ABHD5, AGPAT9
Histamine degradation ALDH1A1, ALDH2
IL-1 signaling FOS, GNAT2, GNA12, GNG2, PRKAR1A
RhoA signaling LPAR6,ARHGEF12, GNA12, ROCK1, CDC42EP2, ARHGAP9
Cell cycle: G1/S checkpoint regulation RPL5, E2F2, NRG1, TFDP1
Salvage pathways of pyrimidine ribonucleotides SGK1, AK5, CDK8, NME4, AKT2
Atherosclerosis signaling S100A8, TNFRSF14, IL1RN, IL1B, MMP9, ORM1
Docosahexaenoic acid (DHA) signaling IL1B, BCL2L1, AKT2
SAPK/JNK signalinga MAP4K5, GNA12, GNG2, GAB1, MAP3K3
Aryl hydrocarbon receptor signaling FOS, NCOR2, HSPB1, IL1B, ALDH1A1, NQO2, ALDH5A1, NFIA, MGST1, TFDP1, MGST3, NRIP1
aPathways which were also modulated at TW24.
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develop depression but had not yet developed it. As such, gene
expression changes at TW4 could be conceptualized as early
biological changes associated with future depression develop-
ment, rather than as a consequence of a depressive status. In
this regard, our findings are consistent with those of Capuron
et al (2003) and Schlaak et al (2012), who have demonstrated
that cortisol responses and, respectively, gene expression
changes, after the first injection of IFN-α, predict the
development of depression after 12 weeks of treatment.
Our findings confirm and extend previous gene expression
studies in patients with IFN-α-induced depression. Felger et al
(2012) used a different transcriptomics approach (isolated
PBMCs and cross-sectional comparison at week 12).
In relation to depression, they found two genes differentially
regulated in those who develop depression: OAS2
(upregulated) and FCER1A (downregulated). We also found
that these two genes were regulated in the same direction by
IFN-α and found the change in OAS2 to be larger in patients
who developed depression than in those who did not
(FC=+4.13 vs FC=+3.06, respectively). Krueger et al
(2011), Birerdinc et al (2012), and Pawlowski et al (2014)
all used a candidate gene approach focused on key immune
genes only and in smaller samples. They all found a variety
of cytokines or cytokine target genes differentially modulated
in depressed patients. Although we do not directly replicate
any of these specific genes, we find an involvement of
several inflammatory pathways including IL-6, IL-1,
IL-8, and NF-κB. Finally, in their transcriptomics study,
Schlaak et al (2012) identified 15 genes regulated 12 h after
the first injection of IFN-α in 11 patients who developed
depression (in comparison with 11 patients who did not
develop depression). Although we do not replicate these
genes exactly, we find five genes belonging to the same
family of genes (guanylate-binding proteins, glutaredoxins,
proteasome subunit-βtype, TNF superfamily members, and
zinc finger proteins).
Our pathway analysis data show that patients who develop
depression also exhibit modulation in oxidative stress
pathways such as NRF2-mediated oxidative stress response,
the glutathione redox reactions I, and production of nitric
oxide and reactive oxygen species in macrophages pathways.
Glutathione has an important role in detoxifying various
reactive oxygen species, which are known to induce oxidative
stress (Franco et al, 2007). This finding is consistent with the
evidence that depression is associated with increased
oxidative and nitrosative stress, both in humans and in
animal models (Bakunina et al, 2015). We also demonstrate
the involvement of neuroplasticity pathways such as ERK5
signaling. Indeed, major depressive disorder may involve
a reduced ability of neuronal systems to show adaptive
plasticity, especially under stress conditions. There is
a wealth of evidence, indicating reductions in various
neurotrophic factors in the plasma and serum, and more
recently also in the gene expression, of depressed patients
(Cattaneo et al, 2010; Dwivedi et al, 2005; Otsuki et al, 2008).
ERK5 is a member of the mitogen-activated protein kinase
(MAPK) family that includes ERK1/2, p38, and JNK, and
participates in the neuronal modulation of depression
(Todorovic et al, 2009). Indeed, the modulation of the
ERK5 signaling pathway is accompanied by alterations
in the SAPK/JNK signaling pathway in our patients who
develop IFN-α-induced depression. Although ERK5 has not
previously been implicated in the development of
IFN-α-induced depression, activation of p38 MAPK in
peripheral blood lymphocytes following the initial injection
of IFN-α has been shown to be implicated (Felger et al,
2011). One mechanism through which p38 MAPK can be
depressogenic is by increasing the activity and expression of
the serotonin transporter and by inhibiting GR function
(Wang et al, 2004). This is in keeping with our finding
for a modulation of the GR signaling pathway, specifically in
our depressed group. Reduced GR function (glucocorticoid
resistance) coupled with high levels of cortisol is an indicator
of hypothalamic–pituitary–adrenal axis dysfunction and is
one of the most replicated biological findings in depression,
demonstrated also in gene expression studies (Matsubara
et al, 2006). Glucocorticoid resistance has also been
hypothesized to underlie the enhanced inflammation de-
scribed in major depression (Pariante and Lightman, 2008).
We also measured a small number of candidate cytokines
in the plasma of our patients. Although we find a significant
effect of IFN-α treatment in the whole sample, we do not
detect any differences between patients who developed
IFN-α-induced depression and those who did not. Indeed,
previous studies examining peripheral inflammation and
IFN-α-induced depression have produced inconsistent
results. For example, as mentioned previously, Wichers
et al (2006) report a difference in plasma IL-6 levels between
patients who develop IFN-α-induced depression and those
who do not, but no difference in plasma TNF-α levels.
Conversely, Raison et al (2008) report increased plasma
TNF-α concentrations to be significantly correlated with
increased depression scores but no correlation was observed
for IL-6. One study found no effect of IFN-α itself on plasma
levels of key cytokines but instead found an increase in CSF
concentrations (Raison et al, 2009). Although we found an
effect of IFN-α on increasing IL-6, IL-17A, and TNF-α, in
general these studies and our findings confirm the notion
that peripheral cytokines are not an accurate biomarker with
reference to the effects of IFN-α. As such, we believe
investigating gene expression is a more accurate and reliable
method, and indeed none of the previous gene expression
studies conducted in IFN-α-induced depression measured
peripheral levels of cytokines.
Our findings are both biologically and clinically relevant.
Studying such a clearly defined patient group at ‘very high
risk’ of developing depression within a few weeks is a useful
model to understand the pathogenesis of depression,
especially depression in the context of enhanced inflamma-
tion, as it has been described after exposures to childhood
trauma (Danese et al, 2008) or due to genetic predisposition
(Bufalino et al, 2013). Of note, a recent transcriptomics study
identified similar gene expression changes (in IL-6 and
NF-κB signaling pathways) as correlates of antidepressant
response to the TNF antagonist, infliximab, supporting the
notion that our findings are relevant for this broader context
(Mehta et al, 2013). There is also evidence that increased
inflammation is associated with the lack of antidepressant
response (Cattaneo et al, 2013; Guilloux et al, 2015), and
therefore it is possible that the genes identified in our study
are relevant to antidepressant response. Of note, in the
context of HCV infection, biological predictors of IFN-α-
induced depression can still have a role in clinical practice,
even in light of emerging IFN-α-free treatment regimens.
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At present, there are several drugs licenced for use in HCV
infection without IFN-α administration (Ryder, 2015); how-
ever, these treatments are not yet readily available for all viral
genotypes and are highly expensive. As such, IFN-α-induced
depression remains a clinical burden for some populations.
There are some limitations of this study. First, we
acknowledge there are tissue-specific differences in gene
expression patterns and by using whole-blood mRNA we
cannot understand which cell types are responsible for
the changes we observe and how these may reflect changes in
other tissues such as the brain. However, studies have shown
a satisfactory degree of correlation between gene expression
in the blood and in the brain (Cai et al, 2010; Liew et al, 2006;
Sullivan et al, 2006), and indeed, as mentioned above, we
replicate (in peripheral blood) the pattern of IFN-responsive
genes previously described in IFN-α-stimulated neurons
(Wang and Campbell, 2005). Therefore, we believe that this
issue does not detract from the impact our findings. Second,
all of the patients received combination therapy with IFN-α
and the antiviral agent ribavirin. Furthermore, although the
use of antidepressants was an exclusion criterion at baseline,
a very small number of depressed patients were prescribed
antidepressants during IFN-α (n= 2). As such, there may be
some transcriptional and behavioral changes that could have
been influenced by these pharmacological agents.
In conclusion, this study provides several lines of evidence
for the possible molecular mechanisms involved in the
impact of IFN-α on behavior. Beyond IFN-α treatment, the
identified transcriptomics signatures could be used as
biomarkers for the identification of individuals at risk of
developing depression, especially in the context of high
inflammation due to stress, physical illness, or genetic make-
up, or to generate molecular targets for the discovery of new
therapeutics in depression.
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